DHFR

P 218 is a novel DHFR inhibitor with antimalarial activity and antifolate effects and can be used to study Buruli ulcer.

D-156844 (Compound 11a) hydrochloride is an SMN2 promoter activator with an EC₅₀ of 4 nM. It enhances mRNA expression of the mouse SMN in NSC-34 cells and the human SMN2 promoter in fibroblasts from patients with severe type I spinal muscular atrophy (SMA), along with increasing full-length human SMN protein expression. D-156844 hydrochloride can overcome DHFR inhibition and is used in SMA research.

PROTAC DHFR Degrader-1 is a PROTAC degrader that specifically targets the dihydrofolate reductase-thymidylate synthase (DHFR-TS) of Plasmodium falciparum, with a Ki value of 2.01 nM. It shows no inhibitory activity against human DHFR and can inhibit the growth of Plasmodium falciparum, making it useful for research on Plasmodium falciparum and malaria.

EGFR/HER2/DHFR-IN-2 (Compound 4b) serves as an inhibitor for EGFR, HER2, and DHFR, with IC50 values of 0.248, 0.156, and 0.138 μM, respectively.

DHFR-IN-11 (compound 6b) is a DHFR inhibitor with demonstrated inhibitory efficacy against the M.

DHFR-IN-16 (compound 8d) is an inhibitor of dihydrofolate reductase (DHFR) with an IC50 of 0.199 μM, and is valuable for anti-infection research.

DHFR-IN-18 (compound 19D) is a DHFR inhibitor utilized in leukemia-related research.

EGFR/DHFR-IN-1 (Compound 10e) is a dual inhibitor of EGFR and DHFR, with IC50 values of 0.151 µM and 0.541 µM, respectively. It induces cell cycle arrest in the G0-G1 and S phases.

DHFR-IN-21 (compound 5p) is an inhibitor of dihydrofolate reductase.

DHFR-IN-20 (Compound LA1) is an inhibitor of dihydrofolate reductase (DHFR) targeting the malignant strains of the malaria parasite. It exhibits inhibition constants (Kis) of 0.16 nM, 0.30 nM, and 6.6 nM for PfDHFR-WT, PfDHFR-QM, and HsDHFR, respectively. Additionally, DHFR-IN-20 demonstrates antimalarial activity, with IC50 values of 1.4 nM against parasites carrying the wild-type (TM4/8.2) PfDHFR enzyme and 1.6 μM against those with the quadruple mutation (V1/S)PfDHFR.

4-O-Methyldopamine hydrochloride ,with CAS No. 645-33-0, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. 4-O-Methyldopamine hydrochloride provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

CB 3705 is a bio-active chemical.

TH9028 TFA is an effective MTHFD2 inhibitor (IC50=11 nM) that suppresses proliferation in HL-60 cells, AML cells, and T-ALL Jurkat cells.

BION106 is a PROTAC degrader targeting dihydrofolate reductase-thymidylate synthase (DHFR-TS). It exhibits potent antimalarial activity with a Ki value of 2.68 nM against Plasmodium falciparum and a toxicity of 0.2 μM. For mammalian cells, its Ki value exceeds 100 μM and the toxicity is 44.2 μM. BION106 is suitable for antimalarial research.

Anti-Dihydrofolate reductase Antibody (2V859) is an antibody targeting Dihydrofolate reductase. Anti-Dihydrofolate reductase Antibody (2V859) can be used in ELISA, WB, IHC, IP.

DHFR-IN-3 (7-bromoquinazoline-2,4-diamine) is an active biochemical.

WR99210 hydrochloride is a potent inhibitor of Plasmodium falciparum dihydrofolate reductase (pfDHFR), which is a major malarial drug target.

Fanotaprim is a dihydrofolate reductase (DHFR) inhibitor.

Piritrexim isethionate, a fat-soluble DHFR inhibitor, shows efficacy in metastatic urothelial cancer with a 5-day oral regimen.

WR99210 (BRL 6231 free base) is a DHFR inhibitor with antiparasitic activity.